This Cardiovascular Side Effect Issue Also Involves Kombiglyze XR, A Saxagliptin – Metformin Combo Diabetes Medication
SUMMARY: We are monitoring an emerging drug safety issue concerning heart failure in patients using Onglyza or Kombiglyze for type 2 diabetes treatment.
AstraZeneca’s diabetes drugs Onglyza and Kombiglyze, both of which contain the active ingredient saxagliptin, are under scrutiny by the FDA for an apparent association with heart failure hospitalizations which was pointed out by a New England Journal of Medicine (NEJM) study.
For more information you see the February 2014 “FDA Drug Safety Communication: FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR)” Safety Announcement.[Read this article in full at original source]
Strictly Confidential, No Obligation